Skip to main content
OpenTrials
Completed

NCT Number: NCT06301906

Red Yeast Rice for Primary Prevention of Hypercholesterolemia

This two-year observational study will be conducted at the outpatient clinic of the Department of Traditional Chinese Medicine of Taoyuan Chang Gung Hospital from February 26, 2024 to December 31, 2025. This study will enroll 35~55 year-old male patients who are expected to take LipoCol Forte Capsules for primary prevention of hypercholesterolemia. The investigators will collect the TCM constitution questionnaires from patients before taking LipoCol Forte Capsules and every three months after taking the medicine. At the same time, blood will be drawn to detect glycated hemoglobin, fasting blood sugar, insulin, lipids profile, liver and kidney function, creatine kinase, predictive parameters of atherosclerotic cardiovascular disease, and plasma bile acids, etc. Fecal samples will also be collected to analyze the intestinal microbiota and fecal bile acid composition. This study will evaluate the efficacy, durability and safety of LipoCol Forte capsules in the primary prevention of hypercholesterolemia in patients with different constitutions, as well as whether it can reduce the risk of cardiovascular disease, and its influence on bile acid metabolism and intestinal microbiota.

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–55 year

Sex eligibility

Male

Study type

Observational

Primary location

Taoyuan branch of Chang Gung Memorial Hospital

Taoyuan, Taiwan, 333

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 35~55 years old
  • LDL-C≥130mg/dl or patients with diabetes or chronic kidney disease with LDL-C ≥ 100mg/dl
  • expected to receive LipoCol Forte Capsule 600mg bid

Exclusion criteria

  • Have received anti-hyperlipidemic drugs or red yeast rice treatment within the past month;
  • Female;
  • Have experienced rhabdomyolysis or abnormal liver function ALT >72 U/L due to taking red yeast rice;
  • Bleeding diseases, such as abnormal platelets, abnormal coagulation factors, or gastrointestinal tract infection within one month
  • Liver insufficiency ALT >72 U/L or renal insufficiency eGFR < 30 mL/min/1.73 m2;
  • Have ever had coronary heart disease, myocardial infarction or cerebrovascular disease;
  • Stressful situations, including hospitalization or surgery within the past or next month, and cancer still being treated;
  • Uncontrolled hypertension (blood pressure ≥160/100 mmHg);
  • Use antibiotics, probiotics or weight-loss drugs for more than 3 consecutive days within 3 months before inclusion in the study;
  • Drug abuse or poor compliance;
  • Use of traditional Chinese medicine in the past month

Treatment and study plan

LipoCol Forte Capsule 600mg twice a day

Drug

LipoCol Forte Capsule 600mg twice a day for 12 months

Primary outcomes

  1. Low Density Lipoprotein-Cholesterol (LDL-C)

    Time frame: before treatment, and 3, 6, 9, 12 months after treatments

    This study will evaluate the efficacy and durability of LipoCol Forte capsules in the primary prevention of hypercholesterolemia.

Secondary outcomes

  1. 10-Year Atherosclerotic Cardiovascular Disease (ASCVD) Risk

    Time frame: before treatment, and 3, 6, 9, 12 months after treatments

    use ASCVD risk estimator to calculate the 10-Year ASCVD Risk after LipoCol Forte capsules treatment

Sponsors and collaborators

Lead sponsor

Chang Gung Memorial Hospital

Other

Registry information

Official study title

Gut Microbiota and Bile Acids Mediate the Clinical Benefits of Red Yeast Rice for Primary Prevention of Hypercholesterolemia: A Pilot Observational Study

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Mar 8, 2024
Registry last updated
Mar 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.